Three-in-One Nanozyme for Radiosensitization of Bladder Cancer
Yang Li,Yuhan Zhang,Na Feng,Fan Yu,Bin Liu
DOI: https://doi.org/10.2147/ijn.s463242
IF: 7.033
2024-10-27
International Journal of Nanomedicine
Abstract:Yang Li, 1 Yuhan Zhang, 1 Na Feng, 2 Fan Yu, 1 Bin Liu 3 1 Department of Gastroenterology and Hepatology, China-Japan Union Hospital of Jilin University, Changchun, 130033, People's Republic of China; 2 Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, People's Republic of China; 3 Department of Urology, China-Japan Union Hospital of Jilin University, Changchun, 130033, People's Republic of China Correspondence: Fan Yu; Bin Liu, Email ; Purpose: Bladder cancer is a common malignancy of the urinary system and the development of noninvasive therapeutic methods is imperative to avoid radical cystectomy, which results in a poor quality of life for patients. Methods: In this study, ultrasmall copper–palladium nanozymes decorated with cysteamine (CPC) nanoparticles (NPs) were synthesized to enhance the efficacy of radiotherapy (RT) in treating bladder cancer. CPC NPs react with intracellular overexpressed H 2 O 2 in the tumor microenvironment to produce large quantities of reactive oxygen species (ROS) and induce tumor cell apoptosis. Furthermore, the CPC nanozymes can generate ample oxygen within tumors by utilizing H 2 O 2 , addressing hypoxia conditions, and mitigating radioresistance. Additionally, CPC facilitates the oxidation of glutathione (GSH) into oxidized glutathione disulfide (GSSG), blocking the self-repair mechanisms of tumor cells post-treatment. Simultaneously, CPC enhances the ionization energy deposition effect on tumor cells. Results: The results demonstrate an increased level of ROS and an elevation in oxygen content at the tumor site. Importantly, tumor growth was restrained without apparent systemic toxicity during the combined treatment. Conclusion: In summary, this study highlights the potential of CPC nanozyme-mediated radiotherapy as a promising avenue for the effective treatment of bladder cancer and demonstrates its potential for future clinical applications in the synergistic therapy of bladder cancer. Keywords: bladder cancer, radiotherapy, nanozyme, tumor microenvironment, hypoxia The bladder, a muscular organ responsible for urine storage, is susceptible to carcinogenic factors such as smoking and chemical exposure, leading to the annual diagnosis of over 75,000 cases of bladder cancer. 1–3 This malignancy is among the top 10 causes of cancer-related mortality and typically manifests with symptoms such as hematuria, dysuria, and urinary obstruction. 4–6 The predominant treatment approach involves radical cystectomy, often supplemented by adjuvant chemotherapy. 7–10 In cases where surgical intervention is not optimal, alternative modalities, such as bladder-preserving chemoradiotherapy which drugs and ionizing irradiation are applied, are considered for therapeutic management. 11 Nonetheless, the prolonged application of these clinical therapeutic regimens poses the risk of adverse effects or potential disease recurrence, attributed to incomplete treatment or insufficient self-repair mechanisms in cancer cells. 12 Therefore, to overcome the constraints associated with traditional approaches to bladder cancer treatment and enhance the overall quality of life for patients, there is an urgent need for innovative therapeutic strategies. Specifically, novel approaches within the realm of nanotechnology hold promise for addressing the challenges associated with bladder cancer treatment. 13,14 Tumor microenvironment (TME) is characterized by mild acidity, hypoxia, overexpressed H 2 O 2, and glutathione (GSH). 15–17 This distinct microenvironment develops as a result of the rapid proliferation and heightened metabolism of tumor cells, setting them apart from normal tissues. 18 The hypoxic conditions hinder therapeutic efficacy, while the overexpression of H 2 O 2 and GSH potentially diminishes the production of reactive oxygen species (ROS). 19 Consequently, the TME tends to exhibit resistance to therapy, leading to inadequate cancer cell elimination. 20 Addressing this resistance and enhancing therapeutic outcomes necessitates interventions to modulate the TME. Employing an endogenous oxygen generation strategy and augmenting ROS production within tumors become crucial for overcoming these challenges. Catalytical therapy, involving the utilization of enzymes with catalytic properties to modulate the TME, emerges as an innovative and effective antitumor strategy. 21,22 Catalytic therapy which take the advantage of TME to modulate the chemoresistant or radioresistant status adopt enzymes to obta -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology